Status:
WITHDRAWN
Effects of Baclofen on Presynaptic Inhibition in Humans
Lead Sponsor:
University of Alberta
Conditions:
Spasticity, Muscle
Spinal Cord Injuries
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study examines the role of the GABA-B receptor in long-lasting presynaptic inhibition of primary afferents in human participants. Participants will come in for two visits, receiving baclofen (a G...
Detailed Description
The ability to execute purposeful movements relies on sensory information coming from the body. This sensory information tells us where are limbs are in relation to the rest of our body (posture sense...
Eligibility Criteria
Inclusion
- Healthy adults between the ages of 18 and 65 years.
- General good health
Exclusion
- Contraindications to baclofen such as a known hypersensitivity to baclofen, renal impairment, stroke, epilepsy, pregnancy and lactation.
- Injury to peripheral nerves or muscles. Injury to nerves or muscles will confound the interpretation of the spinal reflex data.
- Participants with spinal cord injury already taking oral baclofen to manage spasticity.
Key Trial Info
Start Date :
January 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 17 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04471714
Start Date
January 10 2020
End Date
March 17 2022
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
524 HMRC, University of Alberta
Edmonton, Alberta, Canada, T6G2R3